| Literature DB >> 22829774 |
Courtney A Lovejoy1, Wendi Li, Steven Reisenweber, Supawat Thongthip, Joanne Bruno, Titia de Lange, Saurav De, John H J Petrini, Patricia A Sung, Maria Jasin, Joseph Rosenbluh, Yaara Zwang, Barbara A Weir, Charlie Hatton, Elena Ivanova, Laura Macconaill, Megan Hanna, William C Hahn, Neal F Lue, Roger R Reddel, Yuchen Jiao, Kenneth Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Alan K Meeker.
Abstract
The Alternative Lengthening of Telomeres (ALT) pathway is a telomerase-independent pathway for telomere maintenance that is active in a significant subset of human cancers and in vitro immortalized cell lines. ALT is thought to involve templated extension of telomeres through homologous recombination, but the genetic or epigenetic changes that unleash ALT are not known. Recently, mutations in the ATRX/DAXX chromatin remodeling complex and histone H3.3 were found to correlate with features of ALT in pancreatic neuroendocrine cancers, pediatric glioblastomas, and other tumors of the central nervous system, suggesting that these mutations might contribute to the activation of the ALT pathway in these cancers. We have taken a comprehensive approach to deciphering ALT by applying genomic, molecular biological, and cell biological approaches to a panel of 22 ALT cell lines, including cell lines derived in vitro. Here we show that loss of ATRX protein and mutations in the ATRX gene are hallmarks of ALT-immortalized cell lines. In addition, ALT is associated with extensive genome rearrangements, marked micronucleation, defects in the G2/M checkpoint, and altered double-strand break (DSB) repair. These attributes will facilitate the diagnosis and treatment of ALT positive human cancers.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22829774 PMCID: PMC3400581 DOI: 10.1371/journal.pgen.1002772
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Description of ALT lines used in this study and summary of results.
| Cell Line | Tissue Type | Disease | Transformation | C-circles | ATRX protein | ATRX gene | DAXX protein | DAXX gene | H3F3A gene | Micro-nuclea-tion | G2/M checkpoint initiation | G2/M checkpoint maint | DSB repair | DSB repair | % cells with >10 53BP1 foci | Reference |
| JFCF-6/T.1D | Jejunal fibroblast | CF | SV40 ER | 100* |
|
| normal | wild type | wild type | 8±1.4 |
|
| 0.1±5 | normal | 44 | 60 |
| JFCF-6/T.1L | Jejunal fibroblast | CF | SV40 ER | 303±54 |
|
| normal | wild type | wild type |
|
|
|
|
|
|
|
| JFCF-6/T.1M | Jejunal fibroblast | CF | SV40 ER | 76±7 |
| wild type | normal | wild type | wild type |
|
|
|
|
|
|
|
| JFCF-6/T.1Q | Jejunal fibroblast | CF | SV40 ER | 120±8 |
| wild type | normal | wild type | wild type |
|
|
|
|
| 51 |
|
| JFCF-6/T.1R | Jejunal fibroblast | CF | SV40 ER | 42±7 |
|
| normal | wild type | wild type | 9±3.8 |
|
|
|
| 53 | 11 |
| JFCF-6/T.1J/5H | Jejunal fibroblast | CF | SV40 ER | 217±57 |
|
| normal | wild type | wild type | 9±3.9 |
|
|
|
| 31 | 60 |
| JFCF-6/T.1J/1-3C | Jejunal fibroblast | CF | SV40 ER | 82±16 |
|
| normal | wild type | wild type |
|
|
|
|
| 55 | 38 |
| IIICF/a2 | Breast fibroblast | LF | spontaneous | 402±44 |
| wild type | normal | wild type | wild type |
|
|
|
|
|
| 11 |
| IIICF/c | Breast fibroblast | LF | spontaneous | 125±20 |
| wild type | normal | wild type | wild type |
| 89±1 |
|
|
|
| 61 |
| IIICF-T/A6 | Breast fibroblast | LF | SV40 ER | 199±5 |
| wild type |
| wild type | wild type |
|
|
|
|
|
| 61 |
| IIICF-T/B3 | Breast fibroblast | LF | SV40 ER | 278±45 |
|
| normal | wild type | wild type |
| 82±2 |
|
|
|
| 61 |
| IIICF-E6E7/C4 | Breast fibroblast | LF | HPV | 101±24 |
| wild type | normal | wild type | wild type |
|
|
|
|
|
| 61 |
| IVG-BF.LXSN | Breast fibroblast | LF | spontaneous | 395±89 |
| wild type |
| wild type | wild type |
| 83±2 |
|
|
|
|
|
| LFS-05F-24 | Skin fibroblast | LF | spontaneous | 142±8 | normal | wild type | normal | wild type | wild type |
|
|
|
|
|
| 8 |
| WI38-VA12/2RA | Fetal lung fibroblast | n/a | SV40 | 67±11 |
| wild type | normal | wild type | wild type | 7±2.9 |
|
|
|
| 21, 37 | 61 |
| SUSM-1 | Embryonic liver fibroblast | n/a | chemical | 78±22 |
| wild type | normal | wild type | wild type |
|
|
|
|
| 46, 56 | 61, 62 |
| GM847 | Skin fibroblast | LN | SV40 | 117±5 |
| wild type | normal | wild type | wild type | 6±1.0 |
|
|
|
| 17, 38 | 61 |
| MeT-4A | Pleural mesothelium | n/a | SV40 ER | 50±7 | normal | wild type | normal | wild type | wild type |
|
|
|
|
| 17, 23 | 61 |
| SaOS-2 | Bone | OS | n/a | 661±90 |
| wild type |
| wild type | wild type |
| 71±5 |
|
|
|
| 1 |
| G292 | Bone | OS | n/a | 112±12 |
| wild type |
| wild type | wild type |
| 84±2 |
|
|
| 22. 22 | 1 |
| U-2 OS | Bone | OS | n/a | 104±38 |
|
| normal | wild type | wild type | 7±2.5 | 95±1 | 99±1 |
|
| 7, 9 | 1 |
| SK-LU-1 | Bronchial epithelium | Lung adenocarcinoma | n/a | 323±31 | normal | wild type | normal | wild type | wild type |
|
|
|
|
|
| 1 |
CF, cystic fibrosis; HPV, human papillovirus 16 E6 and E7; LF, Li-Fraumeni syndrome; LN, Lesch-Nyhan syndrome; OS, osteosarcoma; SV40 ER, simian virus 40 early region.
Values are averages of triplicate assays (±SD) with JFCF-6/T.1D set to 100 in each assay and the other values expressed relative to this standard. BJ and HeLa values are below 2.
Bold: aberrant ATRX or DAXX protein in western and/or IF. ATRX western results are from three independent immunoblots. Examples of abnormal IF are given in Figure 1b.
Bold: deletions in ATRX. See Table S1 for details.
Values represent mean % cells with micronuclei and SDs from three independent experiments. See Figure 4. Values for HeLa and BJ/SV40 are <8%. Bold: >10% of cells with micronuclei.
Bold: abnormal G2/M checkpoint initiation (<70% reduction in mitotic index 1 hr after 10 Gy IR). See Figure 5A. Italic: uninterpretable due to low mitotic index. hTERT-RPE (positive control) 89% and ATM-/- GM5849 46%.
Bold: abnormal G2/M checkpoint maintenance (<90% reduction in mitotic index 16 hr after 4.5 Gy IR). See Figure 5b. Italic: low mitotic index at 16 hr in noc. Values for HeLa and BJ/SV40 were 98±2% and 96±3%, respectively.
Bold: slow DSB repair kinetics. See Figure 6A and Figure S8. After 0.5 Gy IR, cells with >10 53BP1 foci were scored at 1 and 24 hr and without IR. Values represent (% at 24 hr)-(% no IR)/(% at 1 hr)-(% no IR). nt: not tested.
Bold: abnormal residual DNA fragmentation 24 hr post IR. See Figure 6B. nt: not tested.
Bold: greater than 60% of cells containing >10 spontaneous 53BP1 foci.
A. Englezou, P. Bonnefin, R. Reddel, unpublished data.
J. Plowman, L. Huschtscha, R. Reddel, unpublished data.
Figure 1Deficiency in ATRX/DAXX correlates with ALT.
A, Immunoblot for ATRX and DAXX in the indicated ALT lines. ATRX was detected with A301-045 (Bethyl Labs). DAXX was detected with A301-353A (Bethyl Labs). Asterisk: cell lines with deletions in the ATRX gene (see Table 1 and Table S2). HeLa cells (blue) were used as a positive control. B, IF for ATRX and DAXX in the indicated cell lines. HeLa cells (blue) are used as a positive control. C, Immunoblot for ATRX in additional non-ALT, positive control cells (blue) relative to the indicated ALT lines. D, Immunoblot showing >90% reduction of ATRX protein in HeLa cells expressing ATRX shRNA592. E, T-SCEs, a measure for telomeric recombination, assessed by Chromosome Orientation (CO)-FISH on metaphases harvested from HeLa cells expressing vector or ATRX shRNA592. The average percentage of T-SCEs from four independent experiments is shown, with a p value derived from a two-tailed, unpaired t test. F, Immunoblot showing >90% reduction of ATRX protein in cells expressing ATRX shRNA590 but not with shRNA589. G, Growth curves showing immortalization of SV40-transformed BJ fibroblasts infected with an hTERT expressing retrovirus but no immortalization after infection with the effective (sh590) and ineffective (sh589) shRNAs to ATRX.
Figure 4Frequent micronucleation in ALT cells may be attributable to loss of ATRX.
A, Examples of micronuclei (arrowheads) in two ALT cell lines. Blue: DAPI stain for DNA. B, Graph showing micronucleation frequencies in the ALT cell lines and two telomerase positive controls (blue). Values are means ±SD from three experiments (>100 nuclei each). Red: cell lines with >10% micronucleation frequency (dashed line). HeLa cells were analyzed once. C, Examples of micronuclei (arrowheads) in HeLa cells expressing two independent ATRX shRNAs (see Figure 1 for immunoblots). D, Graph showing micronucleation frequencies in two telomerase positive cell lines infected with vector or the indicated ATRX shRNAs. Values are means ±SEM from two experiments (200 nuclei each).
Figure 5Many ALT lines have a defect in the G2/M checkpoint initiation and/or maintenance.
A, Bar graph depicting the results of an assay for the initiation of the G2/M checkpoint at 1 hr after irradiation of the indicated cell lines. RPE/hTERT is a positive control (in blue). Mean ± SD for triplicate experiments are shown. B, Bar graph depicting the results of an assay for the maintenance of the G2/M checkpoint at 16 hr after IR. BJ/hTERT/SV40 is a positive control (in blue). Mean ± SD for triplicate experiments are shown. See Table 1 for summary. Cell lines in red have a defect in the G2/M checkpoint.
Figure 6Deficiency in DSB repair in ALT lines.
A, Example of assay for 53BP1 foci in the positive control (BJ/hTERT/SV40, blue) (top) and an ALT line (bottom). Cells were treated as indicated above the panels and stained for DNA with DAPI (blue) in conjunction with IF for 53BP1 (green). Note the higher level of 53BP1 foci in non-irradiated ALT cells and incomplete DSB repair at 24 hr after IR. B, Example of PFGE-assay for DSB repair in the indicated cell lines. Cells were treated with 100 Gy IR 24 hr before harvesting and residual DSBs were evaluated based on the DNA fragments released from agarose embedded cells into a PFGE gel. Plugs were treated with 600 Gy to fragment the DNA and run in parallel to serve as a control for loading. DNA was stained with ethidium bromide after electrophoresis. HT1080 (fibrosarcoma cell line) was used as a positive control (in blue).
Figure 2Copy number analysis showing extensive genome rearrangements in ALT lines.
SNP array copy number results are shown for (A) the ALT cell lines and (B) the 1st and 2nd generation subclones derived from JFCF-6/T.1R (indicated by the brackets) and subclones derived from the telomerase-positive HCT116 control. Segmented copy number data is shown for each chromosome, by genomic position in columns and by cell line in rows. The color scale ranges from red (amplification; log2 copy number ratio of 1.5) through white (neutral; 2 copies in diploid lines, log2 ratio of 0) to blue (deletion; log2 ratio of −1.5).
Figure 3Abnormal karyotypes in ALT lines.
Representative metaphases from 5 cell lines showing subtetraploid karyotype with high number of rearranged chromosomes (up to 60%). Structural rearrangements are labeled as following: del(Z)- deletion of chromosome Z; der(Z) - multiple aberrations within single chromosome Z; chromosome, denoted with two or more numbers indicate rearrangement involving two or more partners.